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Abstract
Purpose—To determine how concomitant use of potentially interacting drugs, drug dosage, and
duration of therapy modify the risk of hip fracture associated with use of benzodiazepines and
related drugs (BDZ) in older adults.
Methods—A nested case-control study was conducted in Medicare patients 65 years or older,
enrolled in the Pennsylvania drug assistance program (PACE) between 1994 and 2005. We
included 17,198 patients with a hip fracture leading to hospitalization and 85,990 controls matched
on hospitalization (index date). BDZ and interacting drug use within two weeks preceding the
index date was determined using information on date of drug dispensing, days supplied, quantity
dispensed, and strength. Date of the first BDZ prescription within the year preceding the index
date was used as surrogate for duration of therapy.
Results—While the adjusted relative risk (RR) for overall BDZ use and hip fracture was 1.2
(95% confidence interval 1.1, 1.2), the RRs for concomitant use of alprazolam, lorazepam, and
zolpidem and their interacting drugs were 1.5 (1.3, 1.7), 1.9 (1.7, 2.2), and 1.7 (1.4, 2.0), and 2.1
(1.5, 2.8) for BDZ use initiated within 14 days preceding the index date. RR increased with
increasing BDZ dose and was highest for defined daily BDZ doses >1 (RR: 1.3 (1.2, 1.5)).
Conclusions—BDZ associated hip fracture risk increases with concomitant use of interacting
drugs, higher doses, and is highest at initiation. Clinicians should avoid concomitant use of BDZ
and interacting drugs, because their impact on hip fracture risk is at least additive.
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INTRODUCTION
The association between benzodiazepine use in older adults and the risk of hip fracture is
well established.1,2 However, the risk of hip fracture is likely to be heterogeneous in this
population. Earlier studies indicated an increased risk of hip fracture with long-acting
compounds while short-acting benzodiazepines were not associated with an increased
risk.3,4 More recent studies also reported a higher risk of falls or hip fracture with short-
acting benzodiazepines or zolpidem, a short-acting benzodiazepine related drug.5–8 One
explanation for the apparent discrepancy is that prescribers learned to avoid long-acting
substances in vulnerable older adults.7 For sake of clarity, we will use BDZ from now on to
refer to benzodiazepines and benzodiazepine related drugs.
The increased risk of hip fracture might, however, be rather a function of the concentration
achieved than a function of the half-life of the BDZs and may be highest immediately after
initiation.7,9 The impact of a given dose may be modified by different factors like
concomitant use of interacting drugs altering BDZ plasma concentrations and subsequently
sedative effects. Patient characteristics like liver and renal dysfunction can reduce the
clearance of BDZs or their active metabolites10 and interacting drugs and thereby alter BDZ
effects.
Pharmacodynamic interactions might also lead to an increased risk for adverse effects.
Seventy-one percent of individuals with at least one benzodiazepine prescription who
experienced an injury, including fractures, had used a benzodiazepine-drug combination
classified as a major interaction within 30 days prior to the injury.11 In this population
concomitant use of interacting drugs increased the odds of an injury more than two-fold.11
Neither the association between individual BDZs nor the association between interacting
drugs alone (without BDZs) and the risk of hip fracture were assessed in that study,
however.11
The aim of this study was therefore to determine how factors that are likely to modify (a)
BDZ plasma concentrations like drug dose, concomitant use of pharmacokinetically
interacting drugs, and co-morbidity known to affect clearance, or (b) the effect of BDZs (i.e.
pharmacodynamically interacting drugs and duration of therapy) modify the risk of hip
fracture associated with BDZ use. In particular, we wanted to assess the impact of drugs
potentially interacting with BDZ on the risk of hip fracture in more detail.
METHODS
Study design
We performed a case-control study nested within a cohort of all Medicare patients who were
65 years or older and enrolled in the Pennsylvania drug assistance program (PACE) between
1994 and 2005. We defined cases as hip fracture among outpatients between 1995 and 2005
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leading to hospitalization.12 In case of multiple admissions with hip fracture per person,
only the first was considered.
For each case of hip fracture (N=17,198), five controls (N=85,990) were individually
matched on the month of hospitalization. All controls were assigned the same index date as
the hospital admission date of the corresponding case.
In order to assure that the patients were eligible for medical services and drug benefits for at
least a 12-month period, cases and controls had to have at least one claim for both a non-
prescription service and a prescription each within three 6-month periods before the index
date. To ensure a full drug exposure history,13 cases and controls hospitalized or staying in a
nursing home any time during the three months before the index date were excluded.
The study protocol was approved by the IRB of the Brigham and Women’s Hospital and the
Ethics Committee of the Medical Faculty of the University of Heidelberg.
BDZ exposure
The primary exposure of interest was BDZ use during the 2 weeks prior to the index date.
To categorize use during this time window, we considered all available BDZ (alprazolam,
chlordiazepoxide, clonazepam, clorazepate, diazepam, estazolam, eszopiclone, flurazepam,
halazepam, lorazepam, oxazepam, quazepam, temazepam, triazolam, zaleplon, zolpidem)
dispensed within the 90 days before the index date. We then defined BDZ exposure as
having at least one prescription of a BDZ dispensed extending into the 14 days before the
index date based on the information on the dispensing date and the days supplied. In
agreement with earlier studies7,8,14 a grace period after the calculated end of supply was
chosen because some BDZ have increased half-lives in the elderly or active metabolites
exceeding the half-life of the BDZ by far.10,15 BDZ users were further classified with
respect to BDZ half-life, prescribed dose, and duration of BDZ therapy.
BDZ half-life
Appropriateness of BDZ therapy in the elderly is dichotomously defined depending on BDZ
half-life;16 BDZ were therefore classified as short-acting (half-life ≤24h: alprazolam,
estazolam, lorazepam, oxazepam, temazepam, triazolam, eszopiclone, zaleplon, zolpidem)
and long-acting substances (half-life >24h: chlordiazepoxide, clonazepam, clorazepate,
diazepam, flurazepam, halazepam, quazepam). BDZ users with long- and short-acting BDZ
prescriptions were classified as long-acting BDZ users.
BDZ dose
We calculated the BDZ daily dose from the strength dispensed and by dividing the quantity
of drug dispensed by the days of supply. To standardize daily dose over all BDZ, we divided
the daily dose by the defined daily dose (DDD - World Health Organization). In case of
BZD prescriptions with more than 7 days of overlap based on the days supplied, the overall
daily dose was calculated adding the different prescriptions. With 7 or fewer days of overlap
they were assumed to be early fillings rather than parallel use. The dose was categorized into
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low (daily dose ≤0.5 DDD), medium (0.5 DDD < daily dose ≤1 DDD), and high (daily dose
>1 DDD).
Duration of BDZ use
Duration of BDZ therapy within the year prior to the index date was defined depending on
the first BDZ prescription during the 12 months before the index date. If the first BDZ script
was filled within the 14 days prior to the index date this corresponds to a new user design17
with a wash-out period of approximately 12 months in case of prior exposure. If the first
script was between 10 and 12 months before the index date, however, prevalent use for
many years prior to the exposure assessment period cannot be excluded. BDZ users were
grouped into seven different categories according to the timing of the first BDZ script before
the index date: within 271–360 days, 181–270 days, 91–180 days, 61–90 days, 31–60 days,
15–30 days, and first script within 14 days before the index date.
BDZ-drug interactions
We assessed pharmacokinetic and pharmacodynamic interactions potentially leading to an
increased effect of alprazolam, lorazepam, and zolpidem (the most commonly prescribed
BDZ). We considered strong and moderate inhibitors of cytochrome P450 3A4, the main
isozyme, by which alprazolam and zolpidem are metabolized,18 and all drug-drug
interactions mentioned in Stockley´s,19,20 DRUGDEX,21,22 or summary of product
characteristics of the originator brand.23 The following pharmacokinetically interacting
substances were considered:
Alprazolam 18,19,21,23: Aprepitant, amiodarone, cimetidine, clarithromycin, cyclosporine,
dextropropoxyphen, diltiazem, ergotamine, erythromycin, esomeprazole, fluconazole,
fluoxetine, fluvoxamine, indinavir, isoniazid, itraconazole, ketoconazole, nefazodone,
nelfinavir, nicardipine, nifedipine, omeprazole, paroxetine, propoxyphene, ritonavir,
saquinavir, telithromycin, troleandomycin, and verapamil.
Lorazepam 19,21,23: Valproate and probenecid.
Zolpidem 18,20,22,23: Aprepitant, cimetidine, clarithromycin, diltiazem, erythromycin,
fluconazole, indinavir, itraconazole, ketoconazole, nelfinavir, nefazodone, telithromycin,
ritonavir, saquinavir, and verapamil.
As pharmacodynamically interacting with all BZD we considered the following substances:
Opioids, H1-antihistamines, barbiturates, anticonvulsants, non-benzodiazepine non-
barbiturate hypnotics, antidepressants, neuroleptics, and muscle relaxants.
Presence of a drug-drug interaction was defined as concomitant use of the corresponding
BDZ and at least one prescription of an interacting compound extending into the 14 days
before the index date using the information on the service start date and the days supplied.
BDZ-disease interactions
For alprazolam we assessed the presence of liver disease and chronic renal failure
(International Classification of Diseases (ICD-9) code within the 12 months before the index
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date) as they might modify alprazolam exposure.23 For lorazepam and zolpidem we only
considered liver disease as a condition potentially modifying drug exposure.23
Potentially confounding variables
All potential confounders were defined during the 12-month period before the index date.
For the definition of potential confounders, any ICD-9 code corresponding to the diseases
during the 12 months prior to the index date and dispensed prescription of a drug class
during the 3 months prior to the index date was considered as evidence of the corresponding
condition or use of the corresponding drug class. Due to this definition, which is standard in
analyses of claims data, there are no missing values for any of the confounders except
income (missing in 30 cases and 3 controls). We adjusted all multivariable models for a
variety of patient characteristics, co-morbidity, co-medication, and health care system use.
Analysis
We used crude, age-, gender-, and race-adjusted, and multivariable adjusted logistic
regression models conditioning on each matched set to estimate the incidence rate ratio for
BDZ use and hip fracture using the more general term relative risk (RR) for this measure of
association. When individual BDZ were analyzed, we excluded patients using combinations
of alprazolam, lorazepam, or zolpidem with other BDZs.
The test for dose-response was performed by chi-square test for trend over the ordinal
categories only among BDZ users. A P value <0.05 was considered significant.
To analyze interactions, we used the departure-from-additivity method as described
earlier.24 In these analyses, we included the index year as covariate because individual
matches were broken; we also excluded patients using combinations of alprazolam,
lorazepam, or zolpidem with other BDZs. All analyses were performed using SAS software
version 9.1, SAS Institute Inc., Cary, NC, USA.
RESULTS
Table 1 shows characteristics of the study population. The cases were older, more likely to
be women, and had more frequent BDZ use in the 14 days before the index date compared
to controls. Table 2 lists the characteristics of BDZ use among hip fracture patients and
controls. Alprazolam, lorazepam, and zolpidem were the most frequently prescribed BDZ
which is reflected also in the fact that the greatest proportion of prescribed BDZ was short-
acting. Most of the patients were exposed to low dose BDZ (daily dose ≤0.5 DDD).
The crude and adjusted relative risks (RR) for potential risk factors of hip fracture are shown
in Table 3. BDZ exposure was associated with risk of hip fracture (crude RR=1.30; 95%
confidence interval (CI): 1.24, 1.36). Controlling for socio-demographics, health care
utilization, co-morbidity, and co-medication attenuated the RR for hip fracture (RR=1.16;
95% CI: 1.10, 1.22). Exposure to a short-acting BDZ was associated with an increased
adjusted hip fracture risk (RR=1.19; 95% CI: 1.13, 1.26), whereas long-acting BDZ were
not associated with an increased fracture risk (RR=1.05; 95% CI: 0.94, 1.16). When
focussing on the most frequently prescribed individual substances we found an increased hip
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fracture risk for zolpidem (RR=1.26; 95% CI: 1.11, 1.44) and lorazepam (RR=1.29; 95% CI:
1.19, 1.40), but not for alprazolam (Table 3).
Hip fracture risk increased with increasing BDZ dose (P <0.005) and the highest risk was
observed for BDZ doses >1 DDD (RR=1.32 (95% CI: 1.17, 1.48) (Table 3). The relation
between the date of the first BDZ prescription and the index date as a surrogate of duration
of therapy is shown in Table 3. The highest hip fracture risk was found in those users who
started BDZ use within 14 days preceding the index date (RR=2.05 (95% CI: 1.52, 2.77).
More than 70% of the exposed cases and controls were already exposed to a BDZ within the
271–360 days before the index date indicating long-term use. Cases were more likely to be
on an interacting drug than controls (Table 4). Most potential BDZ-drug interactions were
pharmacodynamic interactions (Table 5). Out of the cases exposed to alprazolam, 72% were
concomitantly exposed to an interacting drug as opposed to 61 % of the controls (Table 4).
The corresponding percentages were 57% of the cases and 43% of the controls for
lorazepam and 59% vs. 50% for zolpidem (Table 4).
Risk of hip fracture was increased for concomitant use of alprazolam and interacting drugs
(RR=1.51; 95% CI: 1.34, 1.69; Table 4) and we found a tendency toward a positive
interaction with a proportion of disease among those with both exposures that is attributable
to their interaction (AP) of 13% (95% CI: 0, 27%). Concomitant use of lorazepam and
interacting drugs (RR=1.94; 95% CI: 1.74, 2.17; Table 4) increased the risk of hip fracture,
too. There was no indication for interaction in terms of a synergistic effect, however, with an
AP of only 3% (95% CI: -10%, +16%). Similarly, for zolpidem and concomitant interacting
drug use risk was increased without indication for interaction (AP 1% (95% CI: -21%,
+22%)).
Combining BDZ-drug interactions and BDZ-disease interactions in separate models had
very little effect on the risk associated with concomitant use of the BDZ and interacting
drugs and there was no meaningful departure from additive risks (data not shown).
DISCUSSION
This study provides a comprehensive analysis of potential modifiers of the association
between BDZ use and risk of hip fracture. Our findings are consistent with previous studies
showing an increased risk of hip fracture associated with overall BDZ use.7,9,25 The risk of
hip fracture associated with BDZ use is highest immediately following initiation of therapy
and increases with higher doses. Concomitant use of alprazolam, lorazepam, and zolpidem
with interacting drugs is associated with an increased risk of hip fracture. In case of
lorazepam we observed an almost two-fold increased risk of hip fracture. Our results are
likely to be clinically important.
Because many of the interacting drugs belong to substance classes that are associated with
an increased risk of hip fracture, a higher risk with concomitant use does not in itself
indicate any interaction between the drugs in the sense of a synergistic effect. When
assessed alone, the interacting drugs were associated with a similar or even larger risk of hip
fracture than BDZ. For lorazepam and zolpidem and their interacting drugs effects appeared
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to be additive, whereas for alprazolam and its interacting drugs we found a tendency toward
a synergistic effect. In both cases, however, concomitant prescribing should be avoided as it
is associated with an increased risk of hip fracture. To our knowledge BDZ-drug interactions
and their impact on hip fracture risk were never analyzed in such detail before.
Our results on possible differences between long- and short-acting BDZ with respect to risk
of hip fracture confirm data from studies showing an increased risk for short-acting
substances.7,9 An explanation for that finding might be a selective prescribing of short-
acting substances to more vulnerable patients. It may also be that patients are preferentially
started on short-acting BDZ and only then switched to long-acting compounds so that the
increased risk observed at the beginning of BDZ therapy may be preferentially attributed to
short-acting BDZ.
We found a dose-response relation over categories of DDD of BDZ use and the risk of hip
fracture thus confirming earlier findings.9 Our findings on changing hazards over time since
initiation of BDZ use confirm previous data with the highest risk observed in new BDZ
users.7,25–27 It is unclear whether the risk reduction over time on drug is a consequence of
adaptive biologic mechanisms or selection of “resistant” people over time (depletion of
susceptibles).28
We found no association between use of alprazolam and hip fracture risk confirming earlier
findings.29,30 For lorazepam our finding of an increased risk is consistent with some9,29 but
not all previous studies.4 For zolpidem we found a smaller risk of hip fracture than an earlier
study,8 which might be due to the larger sample size enabling us to control for a large
variety of potential confounders.
This study has several limitations. First, our analysis is based on drug-dispensing data. We
therefore do not know whether the patients really took the BDZs. The use of drug dispensing
data collected prior to the event for the whole population, however, makes differential
misclassification of exposure unlikely. Non-differential misclassification of exposure cannot
be ruled out and would tend to bias risk estimates towards the null. We only have
information on prescription drugs and thus cannot assess the effects of over-the-counter
(OTC) medications. Most of the drugs potentially modifying the risk of hip fracture are
prescription drugs, however, cimetidine, omeprazole, and H1-antihistamines as OTC drugs
might have been missed. We estimated the daily dose of BDZ based on information on the
days supplied potentially leading to an underestimation of the actual dose if the BDZ is not
taken continuously. In our analysis on duration of BDZ use we cannot exclude the
possibility of BDZ use prior to the exposure assessment period. As the first prescription date
was used as a surrogate for duration of therapy, some misclassification of patients with
intermittent BDZ therapy during the 12 months preceding the index date cannot be ruled out.
We did not expand the exposure time window beyond 12 months because potential adaptive
biologic mechanisms or selection of “resistant” people over time might have already taken
place. Drugs which might decrease rather than increase the effect of alprazolam, lorazepam,
or zolpidem were not taken into account. We assume that effect-increasing drugs would
outweigh the effect of drugs with effect-decreasing properties. The small numbers of
pharmacokinetic interactions precluded evaluation of individual subgroups. We used
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prescriptions of bisphosphonates and other antiosteoporotic drugs as a proxy for severity of
co-morbidity but residual confounding by severity cannot be ruled out. We required
prescription and non-prescription services as proof-of-system use. In a study of drug
interactions in older adults this is very unlikely to limit the generalizability of our findings.
Finally, unmeasured confounding, particularly by indication, is possible, although we
adjusted for a large variety of potentially confounding factors. Confounding by indication
could be present if e.g. the combinations of BDZ with potentially interacting drugs would
have been preferentially prescribed to patients with particularly severe conditions that may
have placed these patients at an increased risk of hip fracture.
In conclusion, our study confirmed that higher doses of BDZ should be avoided and that
patients should be monitored carefully at the beginning of BDZ therapy. Concomitant
prescribing of interacting drugs was associated with a substantially increased risk of hip
fractures. Physicians should therefore carefully monitor such patients and prescribe the
lowest possible doses if the combination cannot be avoided.
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• The general association between benzodiazepine use in older adults and the risk
of hip fracture is well established
• Little is known about the impact of drug-drug interactions on this association
• In this large nested case-control study the risk of hip fracture was substantially
higher in patients concomitantly using benzodiazepines and potentially
interacting drugs
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Table 1





Mean age, years (SD) 84.3 (6.6) 79.5 (7.0)
N (%) N (%)
Gender
  female 15,371 (89.4) 70,792 (82.3)
  male 1,827 (10.6) 15,198 (17.7)
Race
  white 16,779 (97.6) 80,710 (93.9)
  nonwhite 419 (2.4) 5,280 (6.1)
BDZ use 2,840 (16.5) 11,410 (13.3)
Co-medication usea
  Antiparkinson drugs 653 (3.8) 1,582 (1.8)
  Atypical neuroleptics 677 (3.9) 1,263 (1.5)
  Classical neuroleptics 647 (3.8) 1,897 (2.2)
Co-morbiditya
  Degenerative muscle disorders 50 (0.3) 140 (0.2)
  Hemiplegia 312 (1.8) 759 (0.9)
  Delirium 4,121 (24.0) 9,528 (11.1)
  Other fractures 2,666 (15.5) 5,496 (6.4)
mean (SD) mean (SD)
Days in hospital 3.6 (8.9) 2.1 (6.4)
Days in nursing home 2.4 (10.5) 1.0 (6.9)
Annual income ($)b 9,845.5 (3,851.5) 10,293.0 (4,206.0)
Charlson comorbidity score 2.1 (2.1) 1.6 (1.8)
Number of medications 8.7 (5.2) 8.1 (4.9)
Abbreviations: SD, standard deviation; BDZ, benzodiazepines and related drugs.
a
only potentially confounding covariates with the most pronounced effects on hip fracture risk are shown
b
missings: hip fracture patients: N= 30; controls: N= 3
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Table 2
Characteristics of BDZ use in hip fracture patients and controls





N % N %
alprazolam 703 24.8 3,289 28.8
chlordiazepoxide 66 2.3 416 3.7
clonazepam 182 6.4 728 6.4
clorazepate 139 4.9 650 5.7
diazepam 105 3.7 624 5.5
estazolam 22 0.8 85 0.7
eszopiclone 5 0.2 10 0.1
flurazepam 33 1.2 135 1.2
halazepam 0 0 2 0.0
lorazepam 1,071 37.7 3,658 32.1
oxazepam 104 3.7 381 3.3
quazepam 5 0.2 25 0.2
temazepam 81 2.9 212 1.9
triazolam 1 0.0 8 0.1
zaleplon 21 0.7 62 0.5
zolpidem 456 16.1 1,608 14.1
dosage
  low dose (≤0.5 DDD) 1,415 49.8 5,704 50.0
  medium dose 958 33.7 3,794 33.3
  high dose (>1 DDD) 467 16.4 1,912 16.8
half-life
  only long half-life (>24h) 477 16.8 2,412 21.1
  only short half-life (≤24h) 2,315 81.5 8,850 77.6
  both 48 1.7 148 1.3
duration (first script during 12 months prior to index date)
  0–14 days 77 2.7 181 1.6
  15–30 days 60 2.1 182 1.6
  31–60 days 80 2.8 269 2.4
  61–90 days 149 5.3 601 5.3
  91–180 days 150 5.3 495 4.3
  181–270 days 284 10.0 779 6.8
  271–360 days 2,040 71.8 8,903 78.0
Abbreviation: DDD, defined daily dose.
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Table 3
Association between BDZ use during the last 14 days and risk of hip fracture




RR (95% CI) RR (95% CI) RR (95% CI)
no BDZ use 1.00 (ref) 1.00 (ref) 1.00 (ref)
BDZ use 1.30 (1.24, 1.36) 1.32 (1.26, 1.39) 1.16 (1.10, 1.22)
long-acting BDZ 1.07 (0.97, 1.17) 1.18 (1.07, 1.31) 1.05 (0.94, 1.16)
short-acting BDZ 1.36 (1.30, 1.43) 1.36 (1.29, 1.43) 1.19 (1.13, 1.26)
alprazolamb 1.09 (1.00, 1.19) 1.13 (1.03, 1.23) 1.01 (0.92, 1.11)
zolpidemb 1.48 (1.32, 1.66) 1.43 (1.26, 1.62) 1.26 (1.11, 1.44)
lorazepamb 1.50 (1.39, 1.61) 1.48 (1.37, 1.60) 1.29 (1.19, 1.40)
other BDZb 1.14 (1.05, 1.24) 1.21 (1.10, 1.32) 1.08 (0.98, 1.18)
dosage
  low dose (≤0.5 DDD) 1.29 (1.22, 1.37) 1.23 (1.15, 1.31) 1.09 (1.02, 1.17)
  medium dose 1.31 (1.22, 1.41) 1.36 (1.26, 1.47) 1.21 (1.11, 1.31)
  high dose (>1 DDD) 1.27 (1.15, 1.41) 1.58 (1.42, 1.76) 1.32 (1.17, 1.48)
1st BDZ prescription during prior 12 months
  0–14 days (new users) 2.21 (1.70, 2.89) 2.27 (1.70, 3.03) 2.05 (1.52, 2.77)
  15–30 days 1.72 (1.28, 2.30) 1.69 (1.25, 2.30) 1.42 (1.03, 1.96)
  31–60 days 1.55 (1.21, 2.00) 1.71 (1.31, 2.23) 1.34 (1.02, 1.77)
  61–90 days 1.29 (1.08, 1.55) 1.52 (1.26, 1.84) 1.05 (0.86, 1.28)
  91–180 days 1.58 (1.31, 1.89) 1.57 (1.29, 1.90) 1.21 (0.99, 1.48)
  181–270 days 1.90 (1.66, 2.18) 1.89 (1.63, 2.18) 1.53 (1.31, 1.78)
  271–360 days 1.19 (1.13, 1.26) 1.21 (1.15, 1.28) 1.10 (1.04, 1.17)
Abbreviations: RR, relative risk; CI, confidence interval; ref, reference category; BDZ, benzodiazepines and related drugs; DDD, defined daily
dose.
a
adjusted for age at the index date, gender, race, income, health care utilization (number of physician visits, number of different generic drugs
dispensed, number of nursing home days, number of hospital days, mammography, prostate-specific antigen test, Pap smear test,
electrocardiogram, and cholesterol measurement), co-morbidity (delirium, visual impairment, stroke, polyneuropathy, other fractures, osteoporosis,
osteomalacia, multiple sclerosis, palsy, disturbances of equilibrium, degenerative muscle disorders, Charlson co-morbidity score,
hypoalbuminemia, liver disease, chronic renal failure, congestive heart failure, chronic obstructive pulmonary disease, hypercalciuria,
hyperparathyroidism, hyperthyroidism, hypogonadism, hysterectomy, inflammatory bowel disease, lupus erythematosus, oophorectomy,
rheumatoid arthritis, cancer), and co-medication (organic nitrates, statins, thiazolidinediones, sulfonylureas, insulin, anticoagulants, digoxin,
antiarrhythmics, hormone replacement therapy, corticosteroid use, estrogen receptor modulators, anti-osteoporotic drugs, bisphosphonates, proton
pump inhibitors, non-steroidal anti-inflammatory drugs, other anti-inflammatory drugs, acetaminophen, angiotensin II receptor antagonists,
angiotensin-converting enzyme inhibitors, calcium-channel blockers, agents acting on the arteriolar smooth muscle, beta-blockers, other
peripherally or centrally acting antiadrenergic agents, potassium sparing diuretics, thiazides, other low ceiling diuretics, high-ceiling diuretics,
antiparkinson drugs, and the pharmacodynamically interacting substances mentioned above) with a dispensed prescription during the three months
before the index date; no missing values except for income (N= 30 cases; N= 3 controls)
b
patients with a combination of alprazolam, zolpidem, lorazepam, and other BDZ were excluded
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Table 5
Characteristics of concomitant use of interacting drugs.






alprazolam and interacting drug use
  pharmacokinetically interacting co-medicationa 83(0.5) 535(0.6)
  pharmacodynamically interacting co-medicationb 163(1.0) 554(0.7)
  pharmacokinetically and pharmacodynamically interacting co-medicationa,b 221(1.3) 794(0.9)
lorazepam and interacting drug use
  pharmacokinetically interacting co-medicationc 0(0.0) 3(0.0)
  pharmacodynamically interacting co-medicationb 571(3.4) 1501(1.8)
  pharmacokinetically and pharmacodynamically interacting co-medicationb,c 2(0.0) 0(0.0)
zolpidem and interacting drug use
  pharmacokinetically interacting co-medicationd 18(0.1) 90(0.1)
  pharmacodynamically interacting co-medicationb 179(1.1) 480(0.6)
  pharmacokinetically and pharmacodynamically interacting co-medicationb,d 20(0.1) 84(0.1)
a
Aprepitant, amiodarone, cimetidine, clarithromycin, cyclosporine, dextropropoxyphen, diltiazem, ergotamine, erythromycin, esomeprazole,
fluconazole, fluoxetine, fluvoxamine, indinavir, isoniazid, itraconazole, ketoconazole, nefazodone, nelfinavir, nicardipine, nifedipine, omeprazole,
paroxetine, propoxyphene, ritonavir, saquinavir, telithromycin, troleandomycin, and verapamil.
b





Aprepitant, cimetidine, clarithromycin, diltiazem, erythromycin, fluconazole, indinavir, itraconazole, ketoconazole, nelfinavir, nefazodone,
telithromycin, ritonavir, saquinavir, and verapamil.
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